Meningitis Research Foundation Calls for National MenW Vaccination Review

The Meningitis Research Foundation has called for the Joint Committee on Vaccination and Immunisation to undertake an urgent review of the United Kingdom’s vaccination strategy against the MenW strain of meningococcal disease, following the Kent outbreak that spread to 34 confirmed cases with more than 10,000 close contacts traced. The charity argues that the outbreak has exposed gaps in population immunity that the existing immunisation schedule, designed primarily for specific high-risk age groups, may not adequately address.

The current UK immunisation programme includes meningococcal ACWY vaccine for adolescents at around 14 years of age, as part of the school-leaver programme, and for new university students — groups identified as having elevated transmission risk due to social mixing patterns. The programme also provides vaccines for infants as part of the routine early childhood schedule. However, the Kent outbreak included cases in age groups not currently covered by the primary schedule, raising questions about whether the risk profile of MenW in England has shifted in ways that require a broader immunisation approach.

The JCVI, which makes recommendations to ministers about immunisation policy based on cost-effectiveness and epidemiological modelling, had been reviewing meningococcal vaccination policy as part of its regular work programme before the Kent outbreak accelerated the urgency. Meningitis charities have long argued that any outbreak of bacterial meningitis is a preventable tragedy and that the economic case for broader vaccination coverage is robust when the full cost of cases — including treatment, rehabilitation, long-term complications and the impact on affected families — is incorporated into assessments.